Advanced glycation end products in skeletal muscle health and sarcopenia: A systematic review of observational studies

Granic, Antoneta; Hurst, Christopher; Dismore, Lorelle; Dodds, Richard; Witham, Miles; Robinson, Siân; Sayer, Avan A.

doi:10.1016/j.mad.2022.111744

Cited by 11 publications

(6 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The association was robust to adjustment for a range of factors, including other aspects of diet and baseline grip strength, and evident in subgroup and sensitivity analyses. This novel finding suggests a direct effect of UPF on muscle function, potentially via effects on low-grade inflammation [ 88 ] and/or through increased exposure to constituents that are linked to food processing, such as advanced glycation end products [ 89 ]. As diet quality captures high and low consumption of different foods, it provides a more complete assessment of dietary exposure, potentially also contributing to greater consistency across the evidence for dietary patterns than for individual foods.…”

Section: Discussionmentioning

confidence: 99%

The role of nutrition in the prevention of sarcopenia

Robinson,

Granic,

Cruz-Jentoft

et al. 2023

The American Journal of Clinical Nutrition

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

The role of nutrition in the prevention of sarcopenia

Robinson,

Granic,

Cruz-Jentoft

et al. 2023

The American Journal of Clinical Nutrition

Self Cite

View full text Add to dashboard Cite

“…They are characterised by high dynamism and modulate many bodily functions. They are involved in the production of energy needed for movement, maintaining posture, breathing, generating heat, and maintaining homeostasis of metabolic processes [ 248 ]. Skeletal muscles significantly change their structure with age.…”

Section: Age and Muscle Ageingmentioning

confidence: 99%

A Role for Advanced Glycation End Products in Molecular Ageing

Zgutka

Tkacz

Tomasiak

et al. 2023

IJMS

View full text Add to dashboard Cite

Ageing is a composite process that involves numerous changes at the cellular, tissue, organ and whole-body levels. These changes result in decreased functioning of the organism and the development of certain conditions, which ultimately lead to an increased risk of death. Advanced glycation end products (AGEs) are a family of compounds with a diverse chemical nature. They are the products of non-enzymatic reactions between reducing sugars and proteins, lipids or nucleic acids and are synthesised in high amounts in both physiological and pathological conditions. Accumulation of these molecules increases the level of damage to tissue/organs structures (immune elements, connective tissue, brain, pancreatic beta cells, nephrons, and muscles), which consequently triggers the development of age-related diseases, such as diabetes mellitus, neurodegeneration, and cardiovascular and kidney disorders. Irrespective of the role of AGEs in the initiation or progression of chronic disorders, a reduction in their levels would certainly provide health benefits. In this review, we provide an overview of the role of AGEs in these areas. Moreover, we provide examples of lifestyle interventions, such as caloric restriction or physical activities, that may modulate AGE formation and accumulation and help to promote healthy ageing.

show abstract

“…Concentrations of AGEs either in the skin or the circulation are higher in individuals with lower muscle mass and strength [ 73 ], both for the general population [ 74 , 75 ] and for individuals with T2DM [ 76 ]. Some, but not all, of these analyses suggest a dose-response between higher AGEs and lower muscle mass or strength.…”

Section: The Relationship Between Hyperglycaemic States and Skeletal ...mentioning

confidence: 99%

Repurposing Drugs for Diabetes Mellitus as Potential Pharmacological Treatments for Sarcopenia – A Narrative Review

et al. 2023

Self Cite

View full text Add to dashboard Cite

Sarcopenia, the age-related loss of muscle strength and mass or quality, is a common condition with major adverse consequences. Although the pathophysiology is incompletely understood, there are common mechanisms between sarcopenia and the phenomenon of accelerated ageing seen in diabetes mellitus. Drugs currently used to treat type 2 diabetes mellitus may have mechanisms of action that are relevant to the prevention and treatment of sarcopenia, for those with type 2 diabetes and those without diabetes. This review summarises shared pathophysiology between sarcopenia and diabetes mellitus, including the effects of advanced glycation end products, mitochondrial dysfunction, chronic inflammation and changes to the insulin signalling pathway. Cellular and animal models have generated intriguing, albeit mixed, evidence that supports possible beneficial effects on skeletal muscle function for some classes of drugs used to treat diabetes, including metformin and SGLT2 inhibitors. Most human observational and intervention evidence for the effects of these drugs has been derived from populations with type 2 diabetes mellitus, and there is a need for intervention studies for older people with, and at risk of, sarcopenia to further investigate the balance of benefit and risk in these target populations. Not all diabetes treatments will be safe to use in those without diabetes because of variable side effects across classes. However, some agents [including glucagon-like peptide (GLP)-1 receptor agonists and SGLT2 inhibitors] have already demonstrated benefits in populations without diabetes, and it is these agents, along with metformin, that hold out the most promise for further investigation in sarcopenia.Extended author information available on the last page of the article Key PointsType 2 diabetes mellitus and sarcopenia share multiple pathophysiological mechanisms.Preclinical, observational and interventional data suggest that some drugs used to treat diabetes may have beneficial effects on sarcopenia even in patients without diabetes. Clinical trials of these agents have not focussed on enrolling people with sarcopenia, and such trials are needed to evaluate whether diabetes drugs could improve or prevent sarcopenia in patients with or without diabetes.

show abstract

Advanced glycation end products in skeletal muscle health and sarcopenia: A systematic review of observational studies

Cited by 11 publications

References 55 publications

The role of nutrition in the prevention of sarcopenia

The role of nutrition in the prevention of sarcopenia

A Role for Advanced Glycation End Products in Molecular Ageing

Repurposing Drugs for Diabetes Mellitus as Potential Pharmacological Treatments for Sarcopenia – A Narrative Review

Contact Info

Product

Resources

About